Mounjaro (tirzepatide), on the other hand, activates GLP-1 and GIP , which generally produces stronger weight loss outcomes than GLP-1 alone
Interleukin-1 inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS)
Serious side effects can occur with tirzepatide**
Reducing refined sugar and controlling portion sizes amplify the appetite-regulating benefits of GLP-1 therapy
This approach addresses the underlying root causes of their conditions, related comorbidities, medication side effects, and, if recommended, medication tapering
Sodium, potassium, and magnesium are the big three to watch